Nanotechnologies for Targeted Delivery of Cardiovascular Therapeutics Patrick Ching-ho Hsieh1; 1ACADEMIA SINICA, Taipei, Taiwan; PAPER: 8/AdvancedMaterials/Keynote (Oral) SCHEDULED: 11:20/Wed./Guaratiba (60/2nd) ABSTRACT: Human clinical trials of protein or cell therapy for ischemic cardiovascular diseases have shown disappointing outcomes, mainly because of the poor uptake and retention by the targeted site. We aim to develop novel strategies using nanomaterials and nanotechnologies for improving targeted delivery of cardiovascular therapeutics. Several examples will be highlighted, including (1) instructive nanofiber scaffolds with a protein drug VEGF to establish an intramyocardial engineered vascular niche which attracts endogenous stem cells to home to the injury site for tissue regeneration (Lin et al. Sci Transl Med. 2012), (2) functionalized nanoparticles allowing local or systemic injection to prevent thromboembolism or tissue injury following ischemia (Tang et al. ACS Nano. 2012; Chang et al. J Control Release. 2013), (3) a drug capture system using a mixture of hyaluronan hydrogel and anti-PEG antibodies to capture systemically injected PEGylated therapeutics at injection sites (Wu et al. Sci Transl Med. 2016), and (4) platelet-like proteoliposomes which biomimic platelet interactions with circulating monocytes, allowing an EPR-independent drug delivery to the heart infarct (Cheng et al. Adv Healthc Mat. 2016). These strategies improve the efficacy of cardiovascular therapy and can be applied to other biomedical applications. |